z-logo
Premium
Role of Interleukins and Transforming Growth Factor‐β in Chronic Rhinosinusitis and Nasal Polyposis
Author(s) -
Bradley Dewayne T.,
Kountakis Stilianos E.
Publication year - 2005
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/01.mlg.0000161334.67977.5d
Subject(s) - medicine , transforming growth factor , interleukin , chronic rhinosinusitis , inflammation , nasal polyps , sinusitis , maxillary sinus , gastroenterology , endoscopic sinus surgery , immunology , pathology , cytokine , surgery
Objectives: To determine the role of interleukin (IL)‐4, IL‐4 receptor (R), IL‐6, IL‐8, IL‐11, and transforming growth factor (TGF)‐β in chronic rhinosinusitis (CRS) and chronic rhinosinusitis with nasal polyposis (CRS/NP). Methods: Sinus tissue from patients undergoing endoscopic sinus surgery for CRS and CRS/NP was collected. Sinus tissue was then analyzed using reverse‐transcription polymerase chain reaction (RT‐PCR) to detect transcription of IL‐4R, IL‐6, IL‐8, and IL‐11. Sinus tissue samples were also cultured in vitro, treated with IL‐4 for 24 hours, and real‐time PCR was used to quantify the transcription of TGF‐β. Results: Twenty patients were evaluated, 9 with CRS/NP and 11 with CRS alone. The mean age was 43 (20–74) years, with 13 females and 7 males. IL‐4R, IL‐6, IL‐8, and IL‐11 were identified by RT‐PCR in all 20 patients. The transcription of TGF‐β was found to be 3.2 times greater in patients with CRS/NP than in patients with CRS alone ( P = .047). Conclusion: IL‐6, IL‐8, and IL‐11 are nonspecific markers of sinus inflammation being transcribed in patients with CRS and patients with CRS/NP. However, patients with CRS/NP demonstrate increased transcription of TGF‐β in response to IL‐4 treatment, suggesting an IL‐4 mediated mechanism for stromal proliferation in the formation of nasal polyposis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here